PAX2 Gene: Paired Box 2 Transcription Factor

Key regulator of kidney, eye, and ear development; associated with renal coloboma syndrome and Wilms tumor

Gene Information Card

Symbol PAX2
Full Name Paired box 2
Gene Type Protein coding
Chromosomal Location 10q24.31
NCBI Gene ID 5076 ncbi.nlm.nih.gov/gene/5076
Ensembl ID ENSG00000175899
UniProt ID Q02962
OMIM ID 167409
HGNC ID 8616
Aliases FSGS7, PAPB, PAX2A, PAX2B

Description

PAX2 encodes a paired-box homeodomain transcription factor essential for the development of the kidney, ureter, eye, ear, and central nervous system. It regulates cell proliferation, differentiation, and apoptosis during embryogenesis. Mutations in PAX2 cause renal coloboma syndrome (papillorenal syndrome) and are associated with Wilms tumor and focal segmental glomerulosclerosis.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Renal coloboma syndrome (papillorenal syndrome) Loss-of-function mutations disrupt PAX2 DNA binding, impairing kidney and optic nerve development OMIM #120330; ClinVar
Wilms tumor (nephroblastoma) PAX2 overexpression promotes cell survival and proliferation in renal progenitor cells; somatic mutations and copy number gains observed COSMIC; PMID: 10646866
Focal segmental glomerulosclerosis 7 (FSGS7) Missense variants in PAX2 alter transcriptional activity, leading to podocyte dysfunction OMIM #616002; ClinVar

Expression Profile

Tissue Expression
Tissue nTPM level
Kidney 12.5 High
Eye (retina) 8.3 Medium
Inner ear (cochlea) 6.1 Medium
Brain (cerebellum) 4.2 Low
Testis 3.8 Low
Cell Line Expression
Cell Line nTPM Notes
HEK 293 (embryonic kidney) 15.2 High expression; used in functional studies
A-549 (lung carcinoma) 2.1 Low expression
MCF7 (breast cancer) 1.5 Low expression
K562 (leukemia) 0.8 Not detected
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
c.76dupG (p.Val26Glyfs*28) Frameshift Pathogenic; common in renal coloboma syndrome Loss of function
c.70C>T (p.Arg24Trp) Missense Pathogenic; disrupts DNA binding Loss of function
c.418C>T (p.Arg140*) Nonsense Pathogenic; premature truncation Loss of function
c.452G>A (p.Arg151His) Missense Likely pathogenic; altered transactivation Dominant negative
Mutation functional classification

Loss of Function (LOF)

Frameshift, nonsense, and missense mutations that impair DNA binding or nuclear localization, leading to haploinsufficiency in renal coloboma syndrome.

Gain of Function (GOF)

Not well documented; PAX2 overexpression in Wilms tumor may act as an oncogenic gain-of-function through increased cell survival signaling.

Dominant Negative (DN)

Missense variants (e.g., p.Arg151His) that retain DNA binding but fail to activate transcription, interfering with wild-type PAX2 function.

Pathways

PAX2 in kidney development (KEGG: hsa05219 – Bladder cancer; indirect)
Wnt signaling pathway (PAX2 is a downstream target of Wnt/β-catenin)
Retinoic acid signaling (PAX2 expression regulated by retinoic acid during nephrogenesis)
p53 pathway (PAX2 represses p53-mediated apoptosis in kidney progenitors)

Protein Summary

PAX2 is a 417-amino acid transcription factor containing a paired box DNA-binding domain and a partial homeodomain. It binds to specific DNA sequences to activate or repress target genes involved in cell proliferation, migration, and differentiation. During development, PAX2 is critical for the formation of the nephric duct, ureteric bud, optic stalk, and otic vesicle. In adults, PAX2 is expressed at low levels in kidney and eye tissues. Aberrant PAX2 expression is linked to Wilms tumor and other cancers.

Related Products

Product name Cat.No. Species Gene ID
PAX2 Knockout HEK293 Cell Line EDJ-KQ2242 Human 5076 Details Get a Quote
PAX2 Knockout HCT 116 Cell Line EDJ-KQ22536 Human 5076 Details Get a Quote
PAX2 Knockout HeLa Cell Line EDJ-KQ54081 Human 5076 Details Get a Quote
PAX2 Knockout A-549 Cell Line EDJ-KQ62569 Human 5076 Details Get a Quote
Displaying Records 1 To 4 Of 4 Records
Contact Us
*
*
*
*
How did you hear about us: